<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2016.62003</article-id><article-id pub-id-type="publisher-id">WJCR-18767</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20160200000_85249093.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  不同剂量分割放疗IIIB期非小细胞肺癌的疗效及毒性比较
  Analysis of Efficacy and Toxicity of Different Doses Fraction of Radiotherapy for Stage IIIB Non-Small Cell Lung Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>葛</surname><given-names>琴</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蔡</surname><given-names>晶</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谢</surname><given-names>国栋</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>百霞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>金</surname><given-names>建华</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>储</surname><given-names>开岳</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>季忠</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>俞</surname><given-names>岑明</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>葛</surname><given-names>彬彬</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曹</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>南通市肿瘤医院放疗科，江苏 南通</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>geqin.kelley@163.com(葛琴)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>10</month><year>2016</year></pub-date><volume>06</volume><issue>02</issue><fpage>15</fpage><lpage>19</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：比较采用不同剂量分割放疗IIIB期非小细胞肺癌后的疗效及毒性反应。方法：40例IIIB期非小细胞肺癌行三维适形放疗患者，大剂量分割组20例(PTR组)和常规剂量分割组20例(CRT组)，每次治疗前行CBCT扫描验证计划，所有患者均完成处方剂量。计算并比较两组患者放疗后近期疗效及放疗结束3个月内不良反应发生情况。结果：PTR组胸部病灶达CR或PR占40% (8/20)，SD患者占35% (7/20)，PD的患者占25% (5/20)。CRT组胸部病灶达CR或PR占30% (6/20)，SD患者占35% (7/20)，PD的患者占35% (7/20)。所有患者均未出现3~4级不良反应，差异无统计学意义(P &gt; 0.05)。结论：在IIIB期非小细胞肺癌适形放疗中，宜采用大分割放疗，从而提高局控率，缩短疗程，节省时间和资源。 Objective: To compare different doses of radiotherapy in phase IIIB non-small cell lung cancer efficacy and toxicity. Methods: 40 cases of phase IIIB non-small cell lung cancer patients who were treated by three-dimensional conformal radiotherapy were randomly divided into high-dose fraction group (PTR) and conventional fraction group (CRT). All patients completed prescription dose with a CBCT scan validation program before each treatment. The short-term effects of radiotherapy and the incidence of adverse events within 3 months after radiotherapy were calculated and compared between the two groups. Results: PTR Group chest lesions of CR or PR accounted for 40% (8/20), SD patients accounted for 35% (7/20), and PD patients accounted for 25% (5/20). CRT Group chest lesions of CR or PR accounted for 30% (6/20), SD patients accounted for 35% (7/20), and PD patients accounted for 35% (7/20). No patient experienced grade 3 to 4 adverse events, with no significant difference (P &gt; 0.05). Conclusion: High-dose fraction radiation therapy should be selected in the IIIB non-small cell lung cancer conformal radiotherapy, because it can improve the local control rate, shorten the course of treatment, and save time and resources.
    
  
 
</p></abstract><kwd-group><kwd>非小细胞肺癌，放射治疗，剂量分割, Non-Small Cell Lung Cancer</kwd><kwd> Radiation Therapy</kwd><kwd> Dose Fractionation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>不同剂量分割放疗IIIB期非小细胞肺癌的疗效及毒性比较<sup> </sup></title><p>葛琴<sup>*</sup>，蔡晶，谢国栋，杨百霞，金建华，储开岳，赵季忠，俞岑明，葛彬彬，曹飞</p><p>南通市肿瘤医院放疗科，江苏 南通</p><disp-formula id="hanspub.18767-formula1"><graphic xlink:href="http://html.hanspub.org/file/1-2150085x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年10月1日；录用日期：2016年10月15日；发布日期：2016年10月21日</p><disp-formula id="hanspub.18767-formula2"><graphic xlink:href="http://html.hanspub.org/file/1-2150085x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：比较采用不同剂量分割放疗IIIB期非小细胞肺癌后的疗效及毒性反应。方法：40例IIIB期非小细胞肺癌行三维适形放疗患者，大剂量分割组20例(PTR组)和常规剂量分割组20例(CRT组)，每次治疗前行CBCT扫描验证计划，所有患者均完成处方剂量。计算并比较两组患者放疗后近期疗效及放疗结束3个月内不良反应发生情况。结果：PTR组胸部病灶达CR或PR占40% (8/20)，SD患者占35% (7/20)，PD的患者占25% (5/20)。CRT组胸部病灶达CR或PR占30% (6/20)，SD患者占35% (7/20)，PD的患者占35% (7/20)。所有患者均未出现3~4级不良反应，差异无统计学意义(P &gt; 0.05)。结论：在IIIB期非小细胞肺癌适形放疗中，宜采用大分割放疗，从而提高局控率，缩短疗程，节省时间和资源。</p><p>关键词 :非小细胞肺癌，放射治疗，剂量分割</p><disp-formula id="hanspub.18767-formula3"><graphic xlink:href="http://html.hanspub.org/file/1-2150085x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>2014年2月3日，世界卫生组织(WHO)下属的国际癌症研究机构发表的《2014年世界癌症报告》数据显示：2012年新增肺癌患者约180万，并有159万人因肺癌死亡，其中中国病例约占1/3以上 [<xref ref-type="bibr" rid="hanspub.18767-ref1">1</xref>] 。非小细胞肺癌(non-small cell lung cancer, NSCLC)发病率为80%左右，1/3左右患者病期晚，失去手术最佳时机。研究表明，约64.3%的NSCLC患者需要接受放射治疗，45.9%的患者在首程治疗中需要接受放射治疗 [<xref ref-type="bibr" rid="hanspub.18767-ref2">2</xref>] 。大多数NSCLC患者在最初诊断时已处于进展期，存在咯血、胸痛、身体状况较差、远处转移等情况 [<xref ref-type="bibr" rid="hanspub.18767-ref3">3</xref>] ，不适宜采用根治性放疗。近年来，国内外多项研究证实，对于胸部原发病灶采用短疗程、大剂量分割放疗(palliative thoracic radiotherapy, PTR)可以取得更高的临床缓解率甚至更好的生活质量 [<xref ref-type="bibr" rid="hanspub.18767-ref4">4</xref>] - [<xref ref-type="bibr" rid="hanspub.18767-ref7">7</xref>] 。回顾性分析本院2011年7月至2015年6月期间，IIIB期NSCLC患者大剂量分割放疗20例和常规剂量分割放疗(conventional radiation therapy, CRT) 20例，其疗效及毒性比较结果如下。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>我科2011年7月至2015年6月收治的经组织学或病理学证实为ⅢB期NSCLC患者40例，其中1例为食管癌术后肺第二原发、肺功能较差；4例患者同侧肺内多发转移；4例合并内科基础疾病；31例年龄 &gt; 60岁。</p></sec><sec id="s4_2"><title>2.2. 治疗方法</title><p>利用Philips Pinnacle3 9.0计划系统进行靶区勾画。PTR组：大体靶体积(gross target volume, GTV)包括CT上所显示肺部病灶，计划靶体积(planning target volume, PTV)为GTV前后、左右、上下均匀外扩0.5 cm。不做淋巴引流区预防照射。95%等剂量曲线PTV给量50 Gy/10f，5 Gy/f。危及器官剂量限制：TD5/5脊髓Dmax &lt; 45 Gy；食管Dmax &lt; 45 Gy；肺V20 &lt; 28%、V5 &lt; 55%，Dmean &lt; 18 Gy；心脏V30 &lt; 30%。CRT组：GTV为胸部CT上可见病灶，然后在GTV的基础上勾画临床靶体积(clinical target volume, CTV)，病理为腺癌的外放8 mm，鳞癌外放6 mm，转移的淋巴结则外放5 mm，不做淋巴引流区预防照射。再根据摆位误差、呼吸活动度、内脏活动度等因素适当的在CTV基础上外放1.0~2.0 cm形成PTV(可在模拟机下观察器官的活动度)。95%等剂量曲线PTV给量60 Gy/30f，2 Gy/f。危及器官剂量限制：TD5/5脊髓Dmax &lt; 45 Gy；食管Dmax &lt; 45 Gy；肺V20 &lt; 28%、V5 &lt; 55%，Dmean &lt; 18 Gy；心脏V30 &lt; 30%。所有患者均完成处方剂量。</p></sec><sec id="s4_3"><title>2.3. 观察指标</title><p>放疗后胸部病灶疗效评价根据实体瘤疗效评价新标准(Response Evaluation Criteria in Solid Tumors, RECIST)：包括完全缓解(complete response, CR)、部分缓解(partial response, PR)、病情稳定(stable disease, SD)及疾病进展(progressive disease, PD)。近期毒副反应评价采用国际常见不良反应标准第3版(CT⁃CAE v3.0)，主要包括放射性食管炎、放射性肺炎、骨髓抑制及食欲下降。</p></sec><sec id="s4_4"><title>2.4. 统计方法</title><p>用SPSS16.0软件，疗效计算采用Kaplan-Meire法，毒副反应计算采用χ<sup>2</sup>检验。以P &lt; 0.05为差异具统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>随访率为100%，截止2015年11月底末次随访时，PTR组7例(35%)患者死亡，13例(65%)仍生存。常规分割放疗组12例(60%)患者死亡，8例(40%)仍生存。两组肺癌患者放疗后疗效及不良反应比较结果P &gt; 0.05，差异无统计学意义，详见表1、表2。</p></sec><sec id="s6"><title>4. 讨论</title><p>放射治疗的常规剂量分割模式为：1.8~2.0 Gy/fx，5 fx/w，总疗程6~7 w。大分割放疗是指单次剂量 &gt; 2.5 Gy，通过增加单次照射剂量、缩短治疗周期，以减少肿瘤加速再增殖，从而有效地提高肿瘤的局控率。近年来，随着放疗技术飞速发展，随着呼吸门控技术、三维适形放射治疗、调强放疗和图像引导放疗等技术的应用，大分割放疗在肺癌、肝癌、胰腺癌、肾癌、肾上腺癌、脊髓肿瘤及前列腺癌等的治疗中取得了快速发展和良好疗效 [<xref ref-type="bibr" rid="hanspub.18767-ref8">8</xref>] - [<xref ref-type="bibr" rid="hanspub.18767-ref10">10</xref>] 。通过大分割放疗，可以将在7周左右的治疗周期缩短至2周甚至几天。每次分割剂量增大可能增加晚期放射反应，因此，大分割放疗仅用于乏氧及对放射高度抗拒的肿瘤细胞。近年来立体定向放射治疗(stereotactic body radiation therapy, SBRT)的研究和应用逐渐增多，有研究 [<xref ref-type="bibr" rid="hanspub.18767-ref11">11</xref>] - [<xref ref-type="bibr" rid="hanspub.18767-ref14">14</xref>] 显示，SBRT增加了肿瘤照射剂量，降低了周围正常组织受照剂量，缩短了疗程，改善了局部控制率和生存率，且患者耐受性好，是治疗早期NSCLC安全、可行的新手段。对于晚期NSCLC，大分割放疗模式报道甚少。</p><p>本研究结果显示：PTR后胸部病灶达CR或PR占40% (8/20)，SD患者占35% (7/20)，PD的患者占25% (5/20)。所有患者均未出现3~4级不良反应，6例患者出现2级放射性食管炎，其中3例为同步放化</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical cases of lesions in patients after thoracic radiotherapy group</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >分组</th><th align="center" valign="middle"  rowspan="2"  >n</th><th align="center" valign="middle"  colspan="2"  >CR或PR</th><th align="center" valign="middle"  colspan="2"  >SD</th><th align="center" valign="middle"  colspan="2"  >PD</th></tr></thead><tr><td align="center" valign="middle" >例数</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >例数</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >例数</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >PTR组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >CRT组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >35</td></tr></tbody></table></table-wrap><p>表1. 两组患者放疗后胸部病灶疗效情况</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Two groups of patients after radiotherapy recent adverse reactions [cases (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >相关因素</th><th align="center" valign="middle" >PTR组</th><th align="center" valign="middle" >CRT组</th></tr></thead><tr><td align="center" valign="middle" >2级放射性食管炎</td><td align="center" valign="middle" >6 (30.00)</td><td align="center" valign="middle" >8 (40.00)</td></tr><tr><td align="center" valign="middle" >1级放射性食管炎</td><td align="center" valign="middle" >14 (70.00)</td><td align="center" valign="middle" >12 (60.00)</td></tr><tr><td align="center" valign="middle" >2级放射性肺炎</td><td align="center" valign="middle" >6 (30.00)</td><td align="center" valign="middle" >5 (25.00)</td></tr><tr><td align="center" valign="middle" >1级放射性肺炎</td><td align="center" valign="middle" >14 (70.00)</td><td align="center" valign="middle" >15 (75.00)</td></tr><tr><td align="center" valign="middle" >Ⅱ度骨髓抑制</td><td align="center" valign="middle" >8 (40.00)</td><td align="center" valign="middle" >6 (30.00)</td></tr><tr><td align="center" valign="middle" >食欲下降</td><td align="center" valign="middle" >8 (40.00)</td><td align="center" valign="middle" >10 (50.00)</td></tr></tbody></table></table-wrap><p>表2. 两组患者放疗后近期毒副反应情况[例(%)]</p><p>疗患者；14例患者出现1级放射性食管炎；6例患者出现2级放射性肺炎；14例患者出现1级放射性肺炎；8例同步放化疗患者出现Ⅱ度骨髓抑制；8例同步放化疗患者出现2级厌食。常规分割放疗后胸部病灶达CR或PR占30% (6/20)，SD患者占35% (7/20)，PD的患者占35% (7/20)。所有患者均未出现3~4级不良反应，8例患者出现2级放射性食管炎，其中4例为同步放化疗患者；12例患者出现1级放射性食管炎；5例患者出现2级放射性肺炎；15例患者出现1级放射性肺炎；6例同步放化疗患者出现Ⅱ度骨髓抑制；10例同步放化疗患者出现2级厌食。显而易见，与常规分割放疗组相比，大分割放疗局部晚期NSCLC有更高的临床缓解率，且不增加近期不良反应。我们有理由相信，对于接受相同生物效应剂量(biological effective dose, BED)照射的NSCLC患者，大分割放疗除了能增加局部控制率，还可减少治疗次数，节省治疗时间和医疗资源，节省患者费用、减轻患者经济负担 [<xref ref-type="bibr" rid="hanspub.18767-ref15">15</xref>] 。</p><p>该研究的所有患者我们已行血清EGFR、TGF-α检测，两组患者的放疗敏感性与基因表达变化之间的关系有待进一步研究。</p></sec><sec id="s7"><title>文章引用</title><p>葛 琴,蔡 晶,谢国栋,杨百霞,金建华,储开岳,赵季忠,俞岑明,葛彬彬,曹 飞. 不同剂量分割放疗IIIB期非小细胞肺癌的疗效及毒性比较 Analysis of Efficacy and Toxicity of Different Doses Fraction of Radiotherapy for Stage IIIB Non-Small Cell Lung Cancer[J]. 世界肿瘤研究, 2016, 06(02): 15-19. http://dx.doi.org/10.12677/WJCR.2016.62003</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.18767-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">殷蔚柏, 余子豪. 肿瘤放射治疗学[M]. 第4版. 北京: 中国协和医科大学出版社, 2008: 573-608.</mixed-citation></ref><ref id="hanspub.18767-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">袁葆琳, 张涛. 三维适形放射治疗(3DCRT)非小细胞肺癌临床研究[J]. 中国肿瘤临床, 2012( 6): 306-309.</mixed-citation></ref><ref id="hanspub.18767-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Le Péchoux, C. (2011) Role of Post-operative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data. The Oncologist, 16, 672-681. http://dx.doi.org/10.1634/theoncologist.2010-0150</mixed-citation></ref><ref id="hanspub.18767-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Fairchild, A., Harris, K., Barnes, E., et al. (2008) Palliative Thoracic Radiotherapy for Lung Cancer: A Systematic Review. Journal of Clinical Oncology, 26, 4001-4011. http://dx.doi.org/10.1200/JCO.2007.15.3312</mixed-citation></ref><ref id="hanspub.18767-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Bezjak, A., Dixon, P., Brundage, M., et al. (2012) Randomized Phase III Trial of Single versus Fractionated Thoracic Radiation in the Palliation of Patients with Lung Cancer (NCIC CTG SC.15). International Journal of Radiation Oncology*Biology*Physics, 54, 719-728. http://dx.doi.org/10.1016/S0360-3016(02)02989-9</mixed-citation></ref><ref id="hanspub.18767-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">刘维帅, 赵陆军, 刘志艳, 等. 进展期非小细胞肺癌短疗程大分割姑息放疗疗效分析[J]. 中国肿瘤临床, 2013, 40(20): 1240-1243.</mixed-citation></ref><ref id="hanspub.18767-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">沈文斌, 祝淑钗, 高红梅, 等. 三维适形大分割放射治疗局部中晚期非小细胞肺癌的不良反应与长期生存分析[J]. 肿瘤防治研究, 2012, 39(5): 577-581.</mixed-citation></ref><ref id="hanspub.18767-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Beli, I., Koukourakis, G., Platoni, K., et al. (2010) Hypofractionated Radiotherapy in Non Small Cell Lung Cancer: A Review of the Current Literature. Reviews on Recent Clinical Trials, 5, 103-111.  
http://dx.doi.org/10.2174/157488710791233608</mixed-citation></ref><ref id="hanspub.18767-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Salama, J.K. and Vokes, E.E. (2013) New Radiotherapy and Chemoradiotherapy Approaches for Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 31, 1029-1038. http://dx.doi.org/10.1200/JCO.2012.44.5064</mixed-citation></ref><ref id="hanspub.18767-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Partridge, M., Ramos, M., Sardaro, A., et al. (2011) Dose Escalation for Non-Small Cell Lung Cancer: Analysis and Modelling of Published Literature. Radiotherapy &amp; Oncology, 99, 6-11. http://dx.doi.org/10.1016/j.radonc.2011.02.014</mixed-citation></ref><ref id="hanspub.18767-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Taremi, M., Hope, A., Dahele, M., et al. (2012) Stereotactic Body Radiotherapy for Medically Inoperable Lung Cancer: Prospective, Single-Center Study of 108 Consecutive Patients. International Journal of Radiation Oncology*Biology* Physics, 82, 967-973. http://dx.doi.org/10.1016/j.ijrobp.2010.12.039</mixed-citation></ref><ref id="hanspub.18767-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Champeaux-Orange, E., Wachter, T., Bouscayrol, H., et al. (2011) Stereotactic Radiotherapy for Stage I and II Lung Cancer: A Study of 33 Patients. Cancer/Radiothérapie, 15, 192-196. http://dx.doi.org/10.1016/j.canrad.2010.10.002</mixed-citation></ref><ref id="hanspub.18767-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Turzer, M., Brustugun, O.T., Waldeland, E., et al. (2011) Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity. Case Reports in Oncology, 4, 25-34. http://dx.doi.org/10.1159/000324113</mixed-citation></ref><ref id="hanspub.18767-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Andrstschke, N., Zimmermann, F., Boehm, E., et al. (2011) Stereotactic Radiotherapy of Histologically Proven Inoperable Stage I Non-Small Cell Lung Cancer: Patterns of Failure. Radiotherapy &amp; Oncology, 101, 245-249.  
http://dx.doi.org/10.1016/j.radonc.2011.06.009</mixed-citation></ref><ref id="hanspub.18767-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ausborn, N.L., Le, Q.T., Bradley, J.D., et al. (2012) Molecular Profiling to Optimize Treatment in Non-Small Cell Lung Cancer: A Review of Potential Molecular Targets for Radiation Therapy by the Translational Research Program of the Radiation Therapy Oncology Group. International Journal of Radiation Oncology*Biology*Physics, 83, e453- e464. http://dx.doi.org/10.1016/j.ijrobp.2012.01.056</mixed-citation></ref></ref-list></back></article>